A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare.

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Colchicine (Primary)
  • Indications Gouty arthritis; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms AGREE
  • Sponsors Takeda
  • Most Recent Events

    • 08 Nov 2010 Results of poc-hoc tolerability analysis presented at the 74th Annual Scientific Meeting of the American College of Rheumatology
    • 21 Jan 2010 Results published in Arthritis and Rheumatism.
    • 29 Oct 2009 Secondary endpoint results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top